Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

A rationale for early intervention in ER＋ metastatic breast cancer

Published: 1 Sep 2016

Views: 6215

Rating:

Save

Dr Hope Rugo - University of San Francisco Cancer Research Institute, San Francisco, USA

If cancer cells remain after initial treatment, they have a greater likelihood of developing resistance later on in the disease. Using the most effective treatment from the start may help decrease the risk of treatment
resistant cancer cells in the future (Pfizer sponsored).

Visit breastcancervision.com to find out more about the global state of metastatic breast cancer and to learn
about the impact of breast cancer on women, please visit breastcancer-matters.eu.

Related Videos

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer

Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA

Addition of atezolizumab to chemotherapy after surgery does not improve survival for triple negative breast cancer ( Dr Heather McArthur - UT Southwestern Medical Center, Dallas, USA )

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Comment: EBCC 2024 highlights

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)

Comment: EBCC 2024 highlights ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) andDr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status

Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain

Pembrolizumab improves breast cancer outcomes regardless of age or menopausal status ( Dr Javier Cortes - International Breast Cancer Center, Barcelona, Spain )

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer

Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer ( Dr Tim Rattay - University of Leicester Cancer Research Centre, Leicester, UK )

More from ecancer